Intercept Pharmaceuticals Inc (ICPT)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012209
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc (ICPT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intercept Pharma Raises US$30 Million In Series C Financing 10
Partnerships 12
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Enters Into Co-Development Agreement With Servier 14
Licensing Agreements 15
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For INT-747 15
Equity Offering 17
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 17
Intercept Pharma Raises USD202 Million in Public Offering of Shares 19
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 21
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 23
Intercept Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$86 Million 25
Debt Offering 27
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 27
Acquisition 29
Novartis May Acquire Intercept Pharma 29
Intercept Pharmaceuticals Inc – Key Competitors 30
Intercept Pharmaceuticals Inc – Key Employees 31
Intercept Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 34
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 37
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update 39
Nov 03, 2016: Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update 42
Aug 04, 2016: Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update 44
May 05, 2016: Intercept Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update 46
Feb 23, 2016: Intercept Pharmaceuticals Reports 2015 Financial Results and Provides Business Update 47
Corporate Communications 49
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development 49
Jun 09, 2016: Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer 50
Product News 51
Oct 04, 2016: TARGET PharmaSolutions Announces the Launch of TARGET-PBC (Primary Biliary Cholangitis) 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Intercept Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Intercept Pharma Raises US$30 Million In Series C Financing 10
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Enters Into Co-Development Agreement With Servier 14
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For INT-747 15
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 17
Intercept Pharma Raises USD202 Million in Public Offering of Shares 19
Intercept Pharma Completes Public Offering Of Shares For US$192 Million 21
Intercept Pharma Completes Public Offering Of Shares For US$65.7 Million 23
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$86 Million 25
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 27
Novartis May Acquire Intercept Pharma 29
Intercept Pharmaceuticals Inc, Key Competitors 30
Intercept Pharmaceuticals Inc, Key Employees 31
Intercept Pharmaceuticals Inc, Other Locations 32
Intercept Pharmaceuticals Inc, Subsidiaries 32

★海外企業調査レポート[Intercept Pharmaceuticals Inc (ICPT)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gujarat State Petroleum Corp Ltd:企業の戦略的SWOT分析
    Gujarat State Petroleum Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Abcam Plc (ABC):製薬・医療:M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • Liberty Petroleum Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Liberty Petroleum Corp (Liberty) is an independent energy company that explores and develops oil and natural gas reserves. The company provides petroleum exploration properties such as onshore Cooper Eromanga Basin, offshore Gippsland Basin and offshore Browse Basin, among others. It holds p …
  • Zimmer Biomet Holdings Inc.:企業のM&A・事業提携・投資動向
    Zimmer Biomet Holdings Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Zimmer Biomet Holdings Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Enea AB (ENEA):企業の財務・戦略的SWOT分析
    Summary Enea AB (Enea) is a technology company that provides software products, services and solutions. The company’s product portfolio consists of NFV virtualization platforms, operating systems, device and network management, traffic intelligence, 5g data management, access management and policy c …
  • Aviragen Therapeutics Inc (AVIR)-製薬・医療分野:企業M&A・提携分析
    Summary Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, ora …
  • IMPSA SA:企業の戦略的SWOT分析
    IMPSA SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Macrogen Inc (038290):企業の財務・戦略的SWOT分析
    Macrogen Inc (038290) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Asn Bank:企業の戦略・SWOT・財務分析
    Asn Bank - Strategy, SWOT and Corporate Finance Report Summary Asn Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Ana Holdings Inc
    Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • T-Mobile US Inc (TMUS):企業の財務・戦略的SWOT分析
    T-Mobile US Inc (TMUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Hitachi Ltd (6501):企業の財務・戦略的SWOT分析
    Hitachi Ltd (6501) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Severstal:企業の戦略・SWOT・財務分析
    Severstal - Strategy, SWOT and Corporate Finance Report Summary Severstal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • ESSA Pharma Inc (EPI)-製薬・医療分野:企業M&A・提携分析
    Summary Essa Pharma Inc (Essa Pharma) is a clinical-stage pharmaceutical company that carries out the development of small molecule drugs for the treatment castration-resistant prostate cancer (CRPC). The company’s lead product candidate, EPI-506, disrupts androgen receptor (AR) transcriptional acti …
  • Australian Agricultural Company Limited:企業の戦略・SWOT・財務情報
    Australian Agricultural Company Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Agricultural Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Akonni Biosystems Inc-医療機器分野:企業M&A・提携分析
    Summary Akonni Biosystems Inc (Akonni Biosystems) is a molecular diagnostics company that develops, manufactures, and distributes integrated molecular diagnostic systems. The company’s products include nucleic acid extraction kits, molecular diagnostic tests, thermal cyclers, microarray readers and …
  • Baloise Holding Ltd (BALN):企業の財務・戦略的SWOT分析
    Baloise Holding Ltd (BALN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Spirit AeroSystems Holdings, Inc.:企業のM&A・事業提携・投資動向
    Spirit AeroSystems Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Spirit AeroSystems Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • China Eastern Airlines Corporation Limited:企業の戦略・SWOT・財務情報
    China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Leprino Foods Co:企業の戦略的SWOT分析
    Leprino Foods Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆